| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: = 99.49%
| ln Vitro |
Dopamine oxidation by hydrobromic acid (0-500 μM, 24 hours) decreases Neuro-2a cell survival and SH-SY5Y cell viability in a concentration-dependent way [1]. Dopamine oxidation with hydrobromic acid (75-150 μM, 0-24 h) stimulates the expression of COX-2. It also promotes the production of pro-inflammatory cytokines such IL-1β and PGE 2 biosynthesis [1]. Dopamine (0-150 μM, 12 h) and nuclear translocation are oxidized by hydrobromic acid [1]. Phosphorylation of p38 is induced by hydrobromic acid oxidation of dopamine (75 μM, 0–12 h) [3].
|
|---|---|
| ln Vivo |
Degeneration of dopaminergic neurons in the substantia nigra is caused by hydrobromic acid oxidation of dopamine (5 μg/2 μL, injected unilaterally into the right striatum) [2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Neuro-2a cells and SH-SY5Y cells Tested Concentrations: 0-500 µM Incubation Duration: 24 or 48 hrs (hours) Experimental Results: Induction of neurotoxicity in Neuro-2a cells and SH-SY5Y cells in a concentration-dependent manner Causes cytotoxicity in SY5Y cells. In Neuro-2a cells, EC50=111 µM (incubation for 24 hrs (hours)) and 109 µM (incubation for 48 hrs (hours)); in SH-SY5Y cells, EC50=118 µM for 24 hrs (hours) and EC50=107 µM for 48 hrs (hours). RT-PCR[1] Cell Types: Neuro-2a cells and SH-SY5Y cells Tested Concentrations: 75 or 150 µM Incubation Duration: 0, 6 or 24 hrs (hours) Experimental Results: Rapid and robust induction of COX-2 in a time-dependent manner. Induces COX-2 activation, characterized by induction of expression and nuclear translocation. PGE2 in the culture medium increased Dramatically by nearly 5-fold in Neuro-2a cells (75 µM) and 3-fold in SH-SY5Y cells (150 µM). The pro-inflammatory cytokine interleukin 1β (IL-1β) was Dramatically upregulated in Neuro-2a cells and SH-SY5Y cells. Apoptosis analysis [3] Cell Types: PC12 cells Tested Concentrations: 0, 25, 50, 75, and 150 μM Incubation Duration: 0, 2, 4, 6, 12, and 20 h Experimental Results: Induced apoptosis of PC12 cells. Increased the activities of caspase-3, -8 and -9 in PC12 cells in a time- and concentration-dependent manner. Increased these caspase activities at 2-4 h and reached a maximum at 12 h. diminished cells with high mitochondrial membrane potential (JC-1 aggregate) in a time- and concentration-dependent manner. Western Blot Analysis[3] Cell Types: PC12 cells Tested Concentrations: 75 μM Incubation Duration: 0, 3, 5, 6, 8, 10, and 12 h Experimental Results: Increased the level of p-p38 in a time-dependent manner. |
| References |
[1]. Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7(1):9459.
[2]. Jin F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008 Dec 14;600(1-3):78-82. [3]. Fujita H et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 Oct 3;1113(1):10-23. [4]. Soto-Otero R et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000 Apr;74(4):1605-12. |
| Molecular Formula |
C8H12BRNO3
|
|---|---|
| Molecular Weight |
250.09
|
| Exact Mass |
249.0001
|
| CAS # |
636-00-0
|
| Related CAS # |
Oxidopamine hydrochloride;28094-15-7
|
| SMILES |
OC1=CC(CCN)=C(O)C=C1O.[H]Br
|
| Synonyms |
6-Hydroxydopamine hydrobromide 6-OHDA hydrobromide6-OHDA HBr 6 OHDA HBr 6OHDA HBr 6-OHDA Hydrobromide 6 OHDA Hydrobromide 6OHDA Hydrobromide 6-Hydroxydopamine Hydrobromide 6Hydroxydopamine Hydrobromide 6 Hydroxydopamine Hydrobromide 6-Hydroxydopamine HBr 6 Hydroxydopamine HBr
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1) .Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~199.93 mM)
H2O : ~20 mg/mL (~79.97 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (199.93 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9986 mL | 19.9928 mL | 39.9856 mL | |
| 5 mM | 0.7997 mL | 3.9986 mL | 7.9971 mL | |
| 10 mM | 0.3999 mL | 1.9993 mL | 3.9986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA